The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have metastatic KRAS G12C-mutated non-small cell lung cancer with brain metastases. The purpose of this study is to evaluate an investigational drug, adagrasib in combination with stereotactic radiosurgery. The safety and effects of the investigational treatment will be assessed for this study.
Participation includes a screening period, stereotactic radiosurgery and ongoing adagrasib treatment as long as the treatment is working, and a longer term follow-up via a clinic visit or a phone call every 3 months to keep track of how you’re doing. The treatment period will include taking adagrasib orally twice a day and stereotactic radiosurgery 3 weeks before or after you begin taking adagrasib. Study-specific tests will be provided at no cost to you.
Additional information can be found here: https://classic.clinicaltrials.gov/ct2/show/NCT06248606
You will not receive compensation or reimbursement for this study.